SWK is an asset management business based in the US. SWK shares (SWKH) are listed on the NASDAQ and all prices are listed in US Dollars. SWK employs 33 staff and has a trailing 12-month revenue of around $46.3 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $19.25 |
|---|---|
| 52-week range | $16.06 - $19.99 |
| 50-day moving average | $18.90 |
| 200-day moving average | $18.38 |
| Wall St. target price | $25.50 |
| PE ratio | 14.406 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $1.33 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $19.25 from 2023-02-03
| 1 week (2023-01-31) | 2.07% |
|---|---|
| 1 month (2023-01-06) | 1.85% |
| 3 months (2022-11-07) | 2.28% |
| 6 months (2022-08-05) | 5.48% |
| 1 year (2022-02-07) | 3.77% |
|---|---|
| 2 years (2021-02-05) | 33.22% |
| 3 years (2020-02-07) | 39.49% |
| 5 years (2018-02-07) | 82.46% |
Valuing SWK stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of SWK's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
SWK's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, SWK shares trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Revenue TTM | $46.3 million |
|---|---|
| Operating margin TTM | 48.22% |
| Gross profit TTM | $48.4 million |
| Return on assets TTM | 5.97% |
| Return on equity TTM | 6.31% |
| Profit margin | 36.67% |
| Book value | $21.62 |
| Market capitalisation | $245.6 million |
TTM: trailing 12 months
We're not expecting SWK to pay a dividend over the next 12 months.
SWK's shares were split on a 1:10 basis on 7 October 2015. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your SWK shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for SWK shares which in turn could have impacted SWK's share price.
Over the last 12 months, SWK's shares have ranged in value from as little as $16.06 up to $19.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while SWK's is 0.3024. This would suggest that SWK's shares are less volatile than average (for this exchange).
SWK Holdings Corporation, a specialty finance company that focuses on the healthcare sector. It operates in two segments, Finance Receivables and Pharmaceutical Development. The company provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. It also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. In addition, the company engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Its product pipeline includes Ovarest, an oral leuprolide tablet to treat endocrine disease. The company was formerly known as Kana Software, Inc.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.